Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan

Jun-Hyeok Kang, Yen-Ling Lai, Wen‐Fang Cheng, Hyun Soo Kim, Kuan‐Ting Kuo, Yu‐Li Chen, Yoo-Young LeeScientific 2020 · DOI

TL;DR

This study investigates prognostic factors for low-grade serous ovarian carcinoma (LGSOC), a rare subtype of ovarian cancer. It finds that unlike high-grade serous ovarian carcinoma (HGSOC), many standard prognostic factors don't significantly impact LGSOC survival, with FIGO stage and complete surgical cytoreduction being the key exceptions. This highlights the need for LGSOC-specific treatment considerations.

What Problem Does This Paper Address?

Epithelial ovarian cancer (EOC) is a significant health concern, often diagnosed at advanced stages. While most EOC cases are high-grade serous ovarian carcinoma (HGSOC), a smaller but distinct subtype, low-grade serous ovarian carcinoma (LGSOC), exists. LGSOC has different clinical characteristics, tumor growth patterns, and chemotherapy responses compared to HGSOC. However, due to its rarity, most research and treatment guidelines have focused on HGSOC, often applying HGSOC prognostic factors to LGSOC without sufficient validation. This leaves a knowledge gap regarding which factors truly influence LGSOC prognosis and whether established HGSOC predictors are applicable. This paper aims to bridge this gap by evaluating the impact of known HGSOC prognostic factors on LGSOC survival.

Methods

This was a retrospective study analyzing data from 84 patients diagnosed with LGSOC between 2000 and 2018 at two academic institutions in Korea and Taiwan. The researchers collected data on patient demographics, tumor characteristics (including FIGO stage), surgical outcomes (residual disease), and chemotherapy details (regimen, cycles, time to chemotherapy). Statistical analyses included:

  • Shapiro-Wilk test for normality.
  • Chi-square or Fisher's exact test for categorical variables.
  • One-way ANOVA or Kruskal-Wallis test for quantitative variables.
  • Kaplan-Meier method with log-rank test for survival curves.
  • Cox proportional hazards model for multivariate analysis to identify independent prognostic factors.

Datasets

The study utilized a dataset of 84 patients histologically confirmed with low-grade serous ovarian cancer, collected retrospectively from Samsung Medical Center (Korea) and National Taiwan University Hospital (Taiwan). No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • LGSOC is not just "less aggressive HGSOC": The study strongly suggests that LGSOC behaves differently enough from HGSOC that prognostic factors applicable to one may not be to the other. This challenges the assumption of a direct translation of HGSOC knowledge.
  • Surgery is paramount for LGSOC: Complete surgical removal of the tumor (no gross residual disease) emerged as the only significant independent prognostic factor for progression-free survival (PFS) in advanced LGSOC. This underscores the critical role of surgical expertise in managing this disease.
  • Chemotherapy's role is less clear-cut: Unlike in HGSOC, factors like the number of chemotherapy cycles and the time interval between surgery and chemotherapy (TTC) did not show a significant association with survival in LGSOC in this study. This hints at potential chemoresistance or a different therapeutic window for LGSOC.
  • FIGO stage still matters, but with nuances: While FIGO stage is a known prognostic factor, the study highlights that even within early stages (Stage I), Stage IC patients showed a trend towards poorer survival, though not statistically significant.

Key Results

  • FIGO Stage: Advanced FIGO stages (III and IV) were associated with significantly shorter median PFS compared to early stages (I and II).
  • Residual Disease: No gross residual disease after primary cytoreductive surgery was a significant independent prognostic factor for PFS in advanced LGSOC (HR 2.45, p=0.045).
  • Multivariate Analysis: In multivariate analysis for PFS and overall survival (OS), age, preoperative CA-125, time interval from surgery to chemotherapy, and the number of adjuvant chemotherapy cycles were not associated with prognosis.
  • Stage I Specifics: Patients with FIGO Stage IC showed a trend towards poorer survival compared to Stage IA and IB, but this did not reach statistical significance.
  • Chemotherapy Cycles: The number of adjuvant chemotherapy cycles did not significantly affect survival in Stage I patients. For advanced stages, while there was a trend, the difference in PFS and OS between patients receiving 0-3 cycles versus 4 or more cycles was not statistically significant.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Design: This limits the ability to establish causality and is subject to biases in data collection.
  • Small Sample Size: The study included 84 patients, which is considered small for rare diseases, potentially limiting statistical power.
  • Lack of Central Pathologic Review: This could lead to misdiagnoses in some cases.
  • No Molecular/Genetic Data: The study did not evaluate molecular markers, which are increasingly important in cancer research.
  • No Hormone Therapy Analysis: The study did not include data on hormone therapy, which is being explored as a treatment option for ER-positive LGSOC.

Future work should focus on prospective studies with larger cohorts, incorporating molecular profiling and investigating the role of novel therapies like aromatase inhibitors. Further research is needed to definitively determine the benefit of adjuvant chemotherapy in LGSOC and to establish LGSOC-specific treatment guidelines.

Summary updated

Abstract

Low-grade ovarian serous carcinoma (LGSOC) has clinical features different from high-grade serous ovarian carcinoma (HGSOC) accounting for the majority of epithelial ovarian cancer. Because of its rarity, previous studies have only focused on the high-grade disease without considering the differences between the two subtypes. This study aimed to evaluate the effect of the clinical prognostic factors known for HGSOC on survival in patients with LGSOC. Based on the Federation of Gynecology and Obstetrics (FIGO) stage, progression-free survival (PFS) was markedly decreased in advanced disease compared with early disease. For stage I, patients with stage IC had poorer survival than those with stage IA and IB regardless of the number of cycles of adjuvant chemotherapy. For advanced disease, no gross residual disease after primary cytoreductive surgery was significantly associated with longer PFS when compared with gross residual disease. In multivariate analysis for PFS and overall survival (OS), age, preoperative CA-125, time interval from surgery to chemotherapy, and the number of cycles of adjuvant chemotherapy were not associated with prognosis. Complete cytoreduction was the only independent prognostic factor for PFS (HR 2.45, p = 0.045). Our study revealed that the known prognostic factors in HGSOC did not show any effect on the survival in LGSOC except for FIGO stage and complete cytoreduction.
BibTeX
@inproceedings{kang2020clinical,
  author = {Jun-Hyeok Kang and Yen-Ling Lai and Wen‐Fang Cheng and Hyun Soo Kim and Kuan‐Ting Kuo and Yu‐Li Chen and Yoo-Young Lee},
  title = {{Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan}},
  booktitle = {Scientific},
  year = {2020},
  doi = {10.1038/s41598-020-77075-1},
}
Figure